Introduction {#s1}
============

Human adenoviruses (HAdVs) are non-enveloped, moderate-sized DNA viruses that cause asymptomatic infection and clinical syndromes, including upper respiratory tract infection, conjunctivitis, gastroenteritis, infections of the urinary tract, and serious systemic infections in immunocompromised individuals [@pone.0011321-Echavarria1], [@pone.0011321-Hierholzer1]. HAdVs are grouped into seven species, A--G, and further subdivided into at least 52 known types. HAdV shedding from the lower GI tract may occur in healthy adults [@pone.0011321-Cunningham1], [@pone.0011321-BuimoviciKlein1], [@pone.0011321-Durepaire1], but is more common in children (where it may represent a primary infection) [@pone.0011321-Cinek1], [@pone.0011321-1], [@pone.0011321-Lew1], [@pone.0011321-Hillis1], immunocompromised individuals [@pone.0011321-Hierholzer1], and persons with HIV infection, particularly those with symptomatic infection and low CD4 counts [@pone.0011321-Cunningham1], [@pone.0011321-Kaljot1], [@pone.0011321-Khoo1], [@pone.0011321-Gonzalez1]. In HIV-infected individuals, HAdV shedding has been associated with lower gastrointestinal symptoms such as diarrhea and proctitis in some [@pone.0011321-Cunningham1], [@pone.0011321-Grohmann1], [@pone.0011321-Schmidt1] but not all studies [@pone.0011321-Durepaire1], [@pone.0011321-Kaljot1], [@pone.0011321-Gonzalez1]. However, in many cases other copathogens are also present, and it remains unclear to what extent HAdVs other than HAdV-40/41 cause symptomatic infection in the lower GI tract.

HAdVs have been widely explored as vector systems for the delivery of therapeutic and immunogenic gene products because of their ability to infect a range of mammalian host cells, their capacity to accommodate substantial genetic inserts, and their generally favorable safety profile. HAdV type 5 (HAd-5) has been most extensively investigated for applications in gene therapy. In the past ten years, recombinant HAdVs, including type 5, have also been used as vectors in the development of vaccines against several human pathogens, including human immunodeficiency virus (HIV)[@pone.0011321-Buchbinder1], malaria [@pone.0011321-Rodriguez1], influenza [@pone.0011321-Hoelscher1], tuberculosis [@pone.0011321-Wang1], and Ebola virus [@pone.0011321-Sullivan1].

Recent studies have indicated that pre-existing humoral immunity to HAdV-5 is associated with reduced immunogenicity to vaccination with recombinant Ad5 vaccines. In the Step Vaccine Study, a phase II test-of-concept study trial of the Merck HIV-1 gag/pol/nef vaccine, men who have sex with men (MSM) with previous exposure to HAdV-5 through natural infection appear to have had at least transiently increased risk of acquiring HIV after vaccination [@pone.0011321-Buchbinder1], [@pone.0011321-Robb1]. The mechanism(s) underlying this observation remain unknown, and may include a spurious association because of the small sample size of the trial, or true biological phenomena such as upregulation of HIV-susceptible target cells within mucosal tissues, and interactions between HAdV-5 immune complexes and dendritic cells resulting in enhanced T cell infection [@pone.0011321-Perreau1]. Recent studies also have demonstrated cross-reactive T cell responses to many human adenoviruses [@pone.0011321-Leen1] (and unpublished data). These observations draw attention to the potentially important role of natural adenovirus infections in influencing responses to recombinant Ad vector vaccines, and highlight the need to more clearly define the epidemiology and virology of natural human adenovirus infections.

Several HAdV types, including HAdV-5, −26, −35 and −48 are presently under active investigation for use as novel HIV, malaria and TB vaccine vectors [@pone.0011321-Rodriguez1], [@pone.0011321-Lemckert1], [@pone.0011321-Vogels1], [@pone.0011321-Radosevic1], [@pone.0011321-Baden1]. To evaluate whether natural HAdV infections are common in MSM at risk for HIV infection, we examined patterns of HAdV shedding from the genital and lower gastrointestinal tract and tested for preexisting neutralizing antibodies to several proposed HAdV vaccine vectors among HIV-infected MSM undergoing intensive longitudinal mucosal sampling.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

The human experimentation guidelines of the US Department of Health and Human Services and the individual institutions were followed in the conduct of the clinical research. The institutional review boards of the University of Washington and the Asociación Civil Impacta Salud y Educación approved the protocol. Participants provided written informed consent and were compensated for travel and related expenses.

Study Subjects {#s2b}
--------------

We retrospectively examined genital and anoscopy swab samples obtained from a cohort study of twenty HIV positive MSM in Lima, Peru participating in a prospective randomized, placebo-controlled cross-over study to determine the effect of HSV-2 suppression with acyclovir (40 orally BID) on plasma HIV levels [@pone.0011321-Zuckerman1]. Study subjects were greater than 18 years of age, with no previous anti-retroviral history and peripheral CD4 counts \>200 cells/uL. This cohort offered several advantages for the study of HAdVs; the lengthy observation period and frequent sampling of both the anal and genital areas permitted sensitive detection of short episodes of subclinical infection, and a determination of whether adenovirus infection of the genital tract was present. Because acyclovir has no known antiviral activity against HAdVs [@pone.0011321-Kurosaki1], [@pone.0011321-Naesens1], the clinical interventions in this cohort allowed an unconfounded study of the prevalence and diversity of adenoviruses infections over time in each participant.

Clinical visits and procedures {#s2c}
------------------------------

Study subjects returned to the clinic 3 times per week for a total of 18 weeks. Swabbing of the anal and genital regions for viral pathogens was performed by two methods. Rectal mucosal swabbing was performed via anoscopy by placing a sterile Dacron-tipped plastic applicator (Puritan Medical Products, Guilford, ME) against the rectal mucosa 3 to 4 cm above the squamocolumnar junction and rotating for approximately 20 seconds. Surface swabbing of the anogenital region was performed by rubbing the swab over the glans and full length of the penis, the scrotum, perianal skin and completed by inserting the swab in the anus and rotating once (360 degrees). Rectal and anogenital swabbing was performed at each clinic visit. To characterize viral shedding between visits, anogenital swabbing was also self-performed by participants at home. Applicator tips were placed in vials containing 1.0 ml proteinase K digestion buffer (100 mM KCl, 25 mM EDTA, 10 mM Tris-HCl pH 8.0, 1% IGEPAL) and stored at −20°C until processing by the laboratory. Home swabs were maintained at room temperature until the nearest clinic visit and then stored as above.

DNA extraction and real-time PCR {#s2d}
--------------------------------

DNA was extracted from 200 uL of proteinase K digestion buffer using the QIAamp 96 DNA Blood Kit (Qiagen, Inc., Valencia, CA) according to manufacturer instructions and eluted in a total of 100 uL AE buffer. Ten uL of the extract was used to amplify adenoviral DNA using a multiplex PCR assay previously validated to detect 51 recognized HAdV types [@pone.0011321-Huang1]. The PCR assays were performed on blinded samples at the University of Washington Clinical Virology Laboratories.

HAdV typing {#s2e}
-----------

An aliquot of DNA from all episodes of HAdV was designated for molecular typing based on nested PCR amplification and sequencing of a partial region of the HAdV hexon gene [@pone.0011321-Gray1], [@pone.0011321-Lu1]; 116 such samples were submitted to the Centers for Disease Control and Prevention laboratory performing these assays. Predicted amino acid sequences of the hexon hypervariable regions 1--6 (corresponding to amino acid position 192--332 of HAdV type 1 \[accession number AP_000512\]) were aligned with HAdV prototype sequences (accession numbers DQ115407- DQ115457) using Clustal X ver. 1.83 implemented in BioEdit ver. 7.0.9.0 [@pone.0011321-Hall1]. Phylogenetic trees were constructed using neighbor-joining method in MEGA version 4.0.2 [@pone.0011321-Tamura1] and midpoint-rooted using minimum F-value optimization. Evolutionary distances were computed using the JTT matrix-based method with all positions containing alignment gaps and missing data eliminated in pair-wise sequence comparisons. For the purpose of this study, HAdVs were typed based on the reference prototype strain that showed the highest sequence identity score at ≥90% and phylogenetic association with ≥90% bootstrap support. HAdV sequences with identity scores \<90% were classified by species, but not assigned a type [@pone.0011321-Lu1], [@pone.0011321-Ebner1]. Sequence submission to GenBank pending manuscript acceptance.

Serum neutralization {#s2f}
--------------------

Neutralizing antibody titers for prototype HAdVs −5, −26, −35 and −48 were determined using a modified microneutralization assay [@pone.0011321-Hierholzer2]. Briefly, 50 µl of heat-inactivated serum (56°C for 30 min) was diluted 1∶10 and then serially 2-fold (Eagle\'s minimal essential medium with 10% fetal calf serum) in 4-fold replicates in a 96-well microtiter plate. Four TCID~50~ units of pretitered virus in 50 µl was added to each well and incubated for 1 h at room temperature after gentle agitation. Fifty µl of A549 cell suspension (400,000 cells/ml) was then added to each well and mixed thoroughly. After incubation for 5 days at 37°C in 5% CO2, the plate was stained with crystal violet. The neutralization titer was defined as the highest serum dilution that fully inhibited 4 TCID~50~ units of virus.

Results {#s3}
=======

A total of 969 rectal swabs were obtained ([Table 1](#pone-0011321-t001){ref-type="table"}). HAdV was detected in 218 samples (22.5%), and 15 of 20 (75%) individuals had HAdV detected at one or more timepoints. For 932 of the rectal samples collected, a concomitant anogenital swab was performed, and HAdV was detected in 97/932 (10.4%) of these samples. In 84/97 (86.6%) of the HAdV-positive anogenital swabs, HAdV was also detected in the corresponding rectal swab collected on the same day. Rectal swabs were also positive on 121 of the days in which no HAdV was detected in the anogenital swab. These data suggested that the source of the adenovirus was invariably the enteric tract, and therefore all further analyses were restricted to samples obtained by anoscopy.

10.1371/journal.pone.0011321.t001

###### Cohort demographics and clinical data.

![](pone.0011321.t001){#pone-0011321-t001-1}

  Demographic data                                                   N
  ------------------------------------------------------------- ------------
  Median Age (range)                                             31 (22,44)
  Gender--male (percent)                                          20 (100)
  Median numbers of sex partners in the last month (range)        1 (0,10)
  Median numbers of sex partners in the last 6 months (range)     4 (1,40)

  Clinical data                                                 N
  ------------------------------------------------------ ----------------
  Number of rectal swabs                                       969
  Median number of rectal swabs per person (range)          49 (33,51)
  Median number of positive swabs per person (range)        11 (0,33)
  Median percent of positive swabs per person (range)     22.8 (0,64.7)
  Median per person mean Log10 Ad copies/ml (range)       3.9 (2.5,5.1)
  Baseline HIV viral load (range)                         4.3 (3.4,5.1)
  Median CD4/mm3 at screen (range)                        406 (232, 869)
  Number of patients who shed adenovirus at least once          15

Demographic, clinical and virologic data obtained from 20 MSM providing rectal swabs over 18 weeks. "Positive swabs" indicate swabs in which adenovirus was detected by real-time PCR. Baseline HIV viral load provided as log~10~ copies/ml plasma on day 1.

HAdV shedding in the rectal mucosa occurred on 21.1% of days sampled (range 2.6--52.5). Mean log~10~ HAdV concentration was 4.1/ml buffer (range 2.2--8.3). The pattern of HAdV shedding in all 15 persons in whom virus shedding was detected is shown in [Figure 1](#pone-0011321-g001){ref-type="fig"}. Enteric infection was characterized by frequent clusters or "bursts" of shedding. HAdV concentrations in rectal swabs varied by episode, but were generally bell-shaped over each "cluster" period. Sequential infections of multiple types were documented in 9 of the 15 shedders. Median CD4 count was 406 cells/µl (range 232--869) and mean plasma HIV-1 level was 4.3 log~10~ copies/ml. CD4 count and plasma HIV-1 load did not differ between participants with and without HAdV shedding (Mann-Whitney, p = 0.349 and p = 0.497, resp.). HAdV shedding patterns did not correlate with shedding of HSV2 or cytomegalovirus (CMV), nor with use of oral acyclovir (data not shown).

![Adenoviral shedding by study day.\
Pattern of HAdV shedding from the lower gastrointestinal tract by study day. Y axis: Log~10~ HAdV titers from rectal swab material. X-axis: study day. Outlined bars: no typing attempted. Black bars: sequence-based HAdV typing performed. Gray bars: serotyping unsuccessful.](pone.0011321.g001){#pone-0011321-g001}

Molecular typing was attempted on a representative subset of samples from each shedder, selected to cover all observed shedding episodes in this cohort (N = 116 samples). Fifty samples could not be definitively assigned to a known HAdV type due to insufficient amplified DNA for sequencing, the presence of a mixed virus infection that could not be resolved or, in a few cases, to significant differences between the sequenced strain and known reference sequences. Among the 56 positive samples successfully sequenced, numerous HAdV types distributed among species B, C, and D were identified ([Table 2](#pone-0011321-t002){ref-type="table"}; [Figure 2](#pone-0011321-g002){ref-type="fig"}). Multiple HAdV types were detected in eight subjects, while only a single type was observed in the remaining seven individuals shedding virus. Four genetically distinct viruses were identified that had \<90% predicted amino acid sequence identity with the prototype viruses, and may therefore represent new types. Three unique genetic variants of HAdV-48 were identified in two study subjects; subject 1004 shed one variant in September followed by a second variant in November, 2003 ([Figure 2](#pone-0011321-g002){ref-type="fig"}). The most prevalent types were HAdV-1 and −33, which were seen in three individuals. The remaining types were each seen in one or two individuals among the 15 shedders.

![Phylogenetic tree of hexon sequences and reference strains.\
Neighbor-joining phylogenetic tree of partial length HAdV hexon gene sequences obtained from 64 clinical samples (blue) and reference strains (red).](pone.0011321.g002){#pone-0011321-g002}

10.1371/journal.pone.0011321.t002

###### Hexon sequence identity with nearest reference strain.

![](pone.0011321.t002){#pone-0011321-t002-2}

  Patient ID    Study Day   Best matching   \% aa identity   2^nd^ best match   \% aa identity
  ------------ ----------- --------------- ---------------- ------------------ ----------------
  1001           8/8/03         Ad14             91.4              Ad50              84.3
  1001           8/15/03        Ad14             91.4              Ad50              84.3
  1001           8/22/03        Ad14             91.4              Ad50              84.3
  1001           9/8/03         Ad17             99.3              Ad26              81.6
  1001           9/12/03       (Ad36)            81.8              Ad33              76.2
  1001           9/29/03       (Ad36)            81.8              Ad33              76.2
  1001          10/31/03        Ad14             91.4              Ad50              84.3
  1001           11/5/03         Ad5             95.6              Ad6               62.5
  1001          11/14/03        Ad14             91.4              Ad50              84.3
  1001           12/8/03       (Ad36)            81.8              Ad33              76.2
  1001          12/12/03     (Ad15/Ad29)         80.6              Ad17              80.2
  1002           9/8/03         Ad33             100               Ad43              81.1
  1002           9/15/03        Ad33             100               Ad43              81.1
  1002           9/26/03        Ad27             99.2              Ad28              83.9
  1002           10/3/03        Ad27             99.2              Ad28              83.9
  1002          10/22/03        Ad26             92.5              Ad17              81.5
  1002          11/10/03         Ad5             95.6              Ad6               62.5
  1002          11/17/03        Ad26             92.5              Ad17              81.5
  1002          11/21/03        Ad26             92.5              Ad17              81.5
  1002           12/1/03        Ad26             92.5              Ad17              81.5
  1002           12/8/03        Ad37             100               Ad13              94.8
  1004           9/1/03         Ad48             95.3              Ad47              82.5
  1004           9/8/03         Ad48             95.3              Ad47              82.5
  1004          11/17/03        Ad48             100               Ad47              84.5
  1004          11/21/03        Ad48             100               Ad47              84.5
  1004          11/26/03        Ad48             100               Ad47              84.5
  1005           8/18/03        Ad32             95.8              Ad9               72.3
  1005          10/17/03       (Ad33)            83.9              Ad36              81.8
  1005          10/22/03       (Ad33)            83.9              Ad36              81.8
  1005          12/10/03         Ad1             100               Ad6               71.5
  1005          12/12/03         Ad1             100               Ad6               71.5
  1006          11/17/03        Ad47             90.6              Ad38              77.9
  1006          11/21/03        Ad47             90.6              Ad38              77.9
  1006           2/23/04        Ad47             90.6              Ad38              77.9
  1006           2/27/04        Ad47             90.6              Ad38              77.9
  1009          10/31/03        Ad47             90.6              Ad38              77.9
  1009          11/21/03        Ad47             90.6              Ad38              77.9
  1010           1/19/04        Ad34             100               Ad14              81.9
  1010           1/23/04        Ad34             100               Ad14              81.9
  1010           1/30/04        Ad34             100               Ad14              81.9
  1010           2/6/04         Ad34             100               Ad14              81.9
  1010           2/13/04        Ad34             100               Ad14              81.9
  1010           2/23/04        Ad34             100               Ad14              81.9
  1011           4/26/04        Ad24             97.9              Ad38              80.4
  1011           5/28/04        Ad24             97.9              Ad38              80.4
  1013           5/5/04         Ad20             95.1              Ad42              80.4
  1014           1/23/04        Ad22             100               Ad48              73.8
  1014           2/2/04         Ad22             100               Ad48              73.8
  1014           3/3/04          Ad1             100               Ad6               71.5
  1014           5/21/04        Ad20             100               Ad42              79.7
  1017           3/26/04        Ad48             95.9              Ad47              82.5
  1017           3/31/04        Ad48             95.9              Ad47              82.5
  1017           4/5/04         Ad48             95.9              Ad47              82.5
  1017           7/12/04       (Ad26)            87.7              Ad45              83.7
  1017           7/16/04       (Ad26)            87.7              Ad45              83.7
  1018           3/19/04        Ad10             93.2              Ad25              81.2
  1018           3/24/04        Ad10             93.2              Ad25              81.2
  1019           4/12/04        Ad32             95.8              Ad9               72.3
  1019           5/24/04        Ad24             97.2              Ad38              80.4
  1019           5/31/04        Ad24             97.2              Ad38              80.4
  1019           7/7/04         Ad32             95.8              Ad9               72.3
  1020           6/16/04         Ad1             100               Ad6               71.5
  1020           6/23/04        Ad37             100               Ad13              94.8
  1020           7/2/04         Ad33             100            Ad39/Ad43            81.1

Predicted partial-length hexon amino acid sequence identity with nearest and second nearest reference sequences, by subject ID and sample collection day for all samples with available sequence data. Sequence relatedness to reference strains is calculated based the percentage of shared amino acids at each position in an alignment of sequences. Samples with no closely matching reference strain (\< 90% sequence identity to known adenoviral types) are denoted by "()", indicating possible new viral types.

Baseline serum neutralizing antibodies to HAdV-5, −26, −35 and −48 were assessed in all study participants. Fourteen of 20 individuals (70%) were seropositive for HAdV-5; 15 of 20 (75%) for HAdV-26; three of 20 (15%) for HAdV-35; and 2 of 20 (10%) for HAdV-48 ([Table 3](#pone-0011321-t003){ref-type="table"}).

10.1371/journal.pone.0011321.t003

###### Baseline serum neutralizing antibody titers by subject.

![](pone.0011321.t003){#pone-0011321-t003-3}

  Subject ID     Ad5 titer   Ad26 titer   Ad35 titer   Ad48 titer
  ------------- ----------- ------------ ------------ ------------
  1001            \>1∶80       \>1∶80        Neg          1∶10
  1002            \>1∶80        Neg          Neg          Neg
  1003             1∶80         Neg          Neg          Neg
  1004            \>1∶80        1∶20         Neg          Neg
  1005              Neg         1∶10         Neg          Neg
  1006            \>1∶80       \>1∶80        Neg          Neg
  1007            \>1∶80       \>1∶80        Neg          Neg
  1008              Neg        \>1∶80        1∶10         Neg
  1009             1∶80         1∶10         Neg          Neg
  1010              Neg        \>1∶80        Neg          Neg
  1011              Neg         Neg          Neg          Neg
  1012             1∶10        \>1∶80        1∶20        \>1∶80
  1013             1∶20         1∶20         Neg          Neg
  1014              Neg        \>1∶80        Neg          Neg
  1015             1∶40         Neg          Neg          Neg
  1016              Neg         Neg          Neg          Neg
  1017             1∶20         1∶40        \>1∶80        Neg
  1018             1∶40         1∶40         Neg          Neg
  1019             1∶80         1∶20         Neg          Neg
  1020             1∶20         1∶40         Neg          Neg
  \% positive       70%         75%          15%          10%

Serum neutralizing antibody titers to HAdV-35, −5, −26 and −48 in each subject at beginning of study.

Discussion {#s4}
==========

In this study, we examined the prevalence and shedding patterns of HAdV from the lower gastrointestinal tract of HIV-positive Peruvian MSM through intensive longitudinal sampling over 18 weeks. We observed viral shedding in 75% of study participants, who collectively yielded at least 20 different HAdV types including four potentially new types and two additional variants of type 48. Several previous studies have examined the prevalence of enteric viruses in a variety of populations [@pone.0011321-Hierholzer1], [@pone.0011321-Cunningham1], [@pone.0011321-BuimoviciKlein1], [@pone.0011321-Durepaire1], [@pone.0011321-Cinek1], [@pone.0011321-1], [@pone.0011321-Lew1], [@pone.0011321-Kaljot1], [@pone.0011321-Khoo1], [@pone.0011321-Gonzalez1], [@pone.0011321-Grohmann1], [@pone.0011321-Schmidt1], [@pone.0011321-Laughon1], [@pone.0011321-Saulsbury1], [@pone.0011321-Gray2], [@pone.0011321-Thea1], [@pone.0011321-RodriguezBaez1], [@pone.0011321-Thomas1], [@pone.0011321-Albrecht1], [@pone.0011321-Horwitz1]. While HAdV infections in otherwise healthy individuals generally manifest as transient infections with complete resolution, numerous studies have demonstrated the potential for these viruses to establish prolonged and/or latent infection in a variety of sites including adenoidal tissue [@pone.0011321-Evans1], peripherally circulating mononuclear cells [@pone.0011321-Horvath1], the urinary tract [@pone.0011321-Horwitz1], the conjunctiva [@pone.0011321-Kaye1], and the GI tract [@pone.0011321-Hillis1], [@pone.0011321-Khoo1].

One striking difference between this report and prior studies is the remarkably high prevalence of HAdV shedding observed in our study. Earlier work has suggested shedding rates ranging from 0--4% in healthy adults and from 0--28% in selected individuals with HIV infection. In contrast, we observed shedding in 75% of study subjects. This large disparity is likely due to the detection methods employed. Few studies have utilized sensitive molecular methods and the frequent sampling entailed in this protocol; past studies have generally relied on electron microscopy, enzyme immunoassays and cytopathogenicity assays for detection of HAdVs, and employed relatively sparse sampling. In our study, HAdV shedding was episodic, occurring on only 30% of days sampled among those excreting virus at any time. It is therefore likely that many instances of viral shedding were missed in studies relying on limited sampling, due to the short duration of viral shedding episodes. We also note that in this study, we have examined HIV-positive persons who might also manifest more frequent or prolonged HAdV reactivity [@pone.0011321-Khoo1], [@pone.0011321-Hierholzer3]. Additionally, we observed that the prevalence of positive neutralizing antibody titers to HAdV-5, HAdV-35 and HAdV-48 were consistent with several previously published reports [@pone.0011321-Vogels1], [@pone.0011321-Abbink1], [@pone.0011321-Thorner1], [@pone.0011321-Mast1]. However, in this cohort, the baseline seroprevalence to HAdV-26 was considerably higher than in most earlier studies, with the exception of one study reporting seroprevalence rates ranging from 12%--88% depending on the geographic region studied [@pone.0011321-Mast1].

In this study, we have defined several previously underappreciated aspects of enteric HAdV infection, including an extremely high prevalence of viral shedding, a high rate of serological immunity to "rare" serotypes, the frequent occurrence of mixed infections, and several new adenoviral serotypes. The methods used in this study do not permit us to conclusively distinguish between incident infection, persistent infection with intermittent viral reactivation, and passive shedding of viral nucleic acids associated with latently infected cells in the absence of viral replication. However, in several subjects, the presence of discrete shedding episodes with rising and falling viral loads is highly suggestive of active replication. PCR detection of adenovirus from the enteric tract has been shown to correlate with presence of infectious virus in non-human primates and humans [@pone.0011321-Roy1], and thus the shedding we have observed in our study is likely reflect the presence of infectious virus. Whether intermittent shedding of the same type of HAdV in several subjects over time indicates low-grade persistent infection or episodic reactivation of latent infection is unclear. We also note that individuals 1002, 1004 and 1017 shed viruses for which the corresponding baseline serologies were negative (HAdV-26, −48 and −48, respectively), suggesting that these episodes were new infections. Sequence-based typing of mixed infections is likely to only identify the predominant genotype present, and novel genetic variants are difficult to identify by the methods used. It is therefore likely that the true diversity of HAdV types present has been underestimated in this study.

This study is limited by modest cohort size, relatively narrow geographical sampling and by the limited serological data presently available. However, our serology results suggest that infection with "rare" HAdVs with and/or without persistent shedding may be more prevalent than previously thought [@pone.0011321-Vogels1], [@pone.0011321-Abbink1], [@pone.0011321-Thorner1] among certain HIV+ MSM populations, and highlight the need to further investigate the prevalence and transmission of HAdVs in sexually active MSM and other populations at high risk of acquiring sexually transmitted diseases. It is presently unknown to what extent the presence of natural adenoviral infections may interact with vaccines based on similar strains. These results must therefore also be considered in the context of vaccine development and immunization efforts using adenoviral vaccine vectors.
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